This segment focuses on providing comprehensive molecular profiling solutions for research and clinical applications. HTG offers a range of instruments, consumables (assay kits), and software designed to automate sample processing and profile various molecular targets, including RNA and DNA. Research and development activities include continuous improvement of the HTG EdgeSeq technology, development of new assay panels, and expansion of the product portfolio. The technologies used include nuclease protection methods and next-generation sequencing (NGS). Therapeutic areas covered include oncology, immunology, and other areas of precision medicine. The patient impact is significant, as these solutions enable more accurate and timely diagnoses, personalized treatment strategies, and improved patient outcomes. HTG's market positioning is based on its proprietary HTG EdgeSeq technology, which offers advantages in terms of automation, sensitivity, and ease of use. Future opportunities include expansion into new therapeutic areas, development of companion diagnostics, and partnerships with pharmaceutical companies. Regulatory and clinical aspects are crucial, as the company seeks FDA approval for its diagnostic assays. Partnerships with companies like Illumina are key to expanding the menu of clinical tests.

This segment focuses on leveraging HTG's molecular profiling technology to support drug discovery and development efforts. The company offers services to biopharmaceutical companies, enabling them to identify and validate drug targets, assess drug efficacy, and stratify patient populations for clinical trials. Research and development activities include the development of new drug discovery tools and services, as well as collaborations with pharmaceutical partners. The technologies used include the HTG EdgeSeq platform and bioinformatics analysis. Therapeutic areas covered include oncology and other areas of unmet medical need. The patient impact is realized through the acceleration of drug development and the identification of more effective and targeted therapies. HTG's market positioning is based on its ability to provide high-quality molecular profiling data and its expertise in drug discovery. Future opportunities include expanding the range of drug discovery services, forming strategic partnerships with pharmaceutical companies, and developing its own pipeline of drug candidates. Regulatory and clinical aspects are important, as the company works with pharmaceutical partners to support clinical trials. Partnerships with pharmaceutical companies are crucial for driving growth in this segment.